These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10709153)

  • 1. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis.
    Lill JS; O'Sullivan T; Bauer LA; Horn JR; Carithers R; Strandness DE; Lau H; Chan K; Thakker K
    J Clin Pharmacol; 2000 Mar; 40(3):250-7. PubMed ID: 10709153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation.
    Gschwend MH; Martin W; Arnold P; Verdun MO; Cambon N; Frentzel A; Scheiwe W
    Arzneimittelforschung; 2005; 55(7):403-13. PubMed ID: 16080280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac.
    Manvelian G; Daniels S; Gibofsky A
    Postgrad Med; 2012 Jan; 124(1):117-23. PubMed ID: 22314121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations.
    Mermelstein F; Hamilton DA; Wright C; Lacouture PG; Ramaiya A; Carr DB
    Pharmacotherapy; 2013 Oct; 33(10):1012-21. PubMed ID: 23744759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac.
    Desjardins PJ; Olugemo K; Solorio D; Young CL
    Clin Ther; 2015 Feb; 37(2):448-61. PubMed ID: 25499666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of a Diclofenac Sodium 75 mg/1 mL Solution (Akis
    Leuratti C; Loprete L; Rossini M; Frangione V; Rovati S; Radicioni M
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):681-689. PubMed ID: 31077065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: a single-dose, randomized, two-way crossover study.
    Scallion R; Moore KA
    Clin Ther; 2009 Oct; 31(10):2233-41. PubMed ID: 19922894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.
    Mukherjee J; Das A; Chakrabarty US; Sahoo B; Sengupta P; Chatterjee B; Roy B; Pal TK
    Arzneimittelforschung; 2010; 60(8):506-9. PubMed ID: 20863007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diclofenac and metabolite pharmacokinetics in children.
    van der Marel CD; Anderson BJ; Rømsing J; Jacqz-Aigrain E; Tibboel D
    Paediatr Anaesth; 2004 Jun; 14(6):443-51. PubMed ID: 15153204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, open-label, 5-way crossover study to evaluate the pharmacokinetic/pharmacodynamic interaction between furosemide and the non-steroidal anti-inflammatory drugs diclofenac and ibuprofen in healthy volunteers.
    Paterson CA; Jacobs D; Rasmussen S; Youngberg SP; McGuinness N
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):477-90. PubMed ID: 21781648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.
    Shimamoto J; Ieiri I; Urae A; Kimura M; Irie S; Kubota T; Chiba K; Ishizaki T; Otsubo K; Higuchi S
    Eur J Clin Pharmacol; 2000 Apr; 56(1):65-8. PubMed ID: 10853880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
    Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
    Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of single and multiple intravenous bolus doses of diclofenac sodium compared with oral diclofenac potassium 50 mg: A randomized, parallel-group, single-center study in healthy subjects.
    Munjal S; Gautam A; Okumu F; McDowell J; Allenby K
    J Clin Pharmacol; 2016 Jan; 56(1):87-95. PubMed ID: 26096889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.
    Davies NM; Anderson KE
    Clin Pharmacokinet; 1997 Sep; 33(3):184-213. PubMed ID: 9314611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of diclofenac sodium 2% and 1.5% topical solutions relative to oral diclofenac sodium in healthy volunteers.
    Holt RJ; Taiwo T; Kent JD
    Postgrad Med; 2015 Aug; 127(6):581-90. PubMed ID: 26077436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of diclofenac potassium at low doses.
    Hinz B; Chevts J; Renner B; Wuttke H; Rau T; Schmidt A; Szelenyi I; Brune K; Werner U
    Br J Clin Pharmacol; 2005 Jan; 59(1):80-4. PubMed ID: 15606444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers.
    Poli A; Moreno RA; Ribeiro W; Dias HB; Moreno H; Muscara MN; De Nucci G
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):76-9. PubMed ID: 8929750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.